Business Development Advisory Board
We at Sunstone are committed to creating a supportive framework for our portfolio companies to enhance the likelihood of successful product development and strategic collaborations. One means to attain this end is through meetings between portfolio companies and the Business Development Advisory Board (BDAB) which we created in 2007.
Sunstone’s BDAB is an external advisory group composed of seasoned business development executives which meets regularly to assist our investment managers in advancing and progressing the portfolio companies, particularly on their business development strategy.
The BDAB meets twice a year, and selected portfolio companies are invited to participate based on company life cycle status and anticipated business events.
The BDAB is composed of a mix of current and former leading Life Science Business Development executives from Europe and the US who have deep knowledge of the pharmaceutical industry, including operational and leadership experience in R&D, commercial and business development functions within small to large-cap life science companies. The BDAB’s diverse, but complementary knowledge and experience provides a multi-facetted and global perspective.
Robert J. Cobuzzi Jr.
Robert J. Cobuzzi Jr, (United States) – Chairman of the BDB, Sunstone Venture Partner, and President and CEO of Diffusion Pharmaceuticals Inc. (Nasdaq:DFFN). Bob was formerly with Endo International plc, most recently as President, Endo Ventures Limited (Ireland). He previously held R&D roles at Adolor, Centocor/JnJ and AstraMerck.
Christine Lemke, (Germany/Switzerland) – Senior Vice President of Portfolio and Growth Strategy, absci. Christine has extensive business development, corporate strategy and R&D experience in leadership positions in the pharmaceutical industry, including as Head of Global Corporate Development at Ferring; SVP, Global Head of R&D Strategy and Planning at Shire and Head of Bayer HealthCare Strategy.
Corinne Venot, PhD, MBA (France) – Executive Director, Head of Business Development Europe, BeiGene, former Business Development at Servier and previously R&D Partnering and Research Scientist at Sanofi-Aventis.
David Colpman (United Kingdom) – Independent Consultant, current Board Director of Oak Hill Bio, former Head of Global Business Development, Shire Pharmaceuticals, and previouly Business Development at GSK and Novo Nordisk.
Juergen Heitmann, (Germany/Netherlands) – Director Business Development and Alliance, Shionogi Europe. Juergen was previously Director of BD at Nordic Pharma and previously held positions at Sensorion, Novartis, Nycomed and Takeda (Switzerland).
Simon Dew (United Kingdom) – Chief Business Officer at ReNeuron Group Plc. Prior to ReNeuron, Simon held senior business development and strategy roles at Mereo, Evox Therapeutics Ltd., Gyroscope Therapeutics, and previously Senior Vice President, Business Development and Corporate Strategy, Astellas Pharma (UK/Japan).
Berthold Hinzen (Denmark) – Transactions, Commercial Business Development & Alliances Management, Novo Nordisk. Former Head of Licensing, Bayer Pharmaceuticals